|
1
|
Pearce L: Haematological cancers. Nurs Stand. 30:152016. View Article : Google Scholar
|
|
2
|
Pérez GB, Calaf GM, Villalba MTM, Prieto KS and Burgos FC: Frequency of hematologic malignancies in the population of Arica, Chile. Oncol Lett. 18:5637–5643. 2019.PubMed/NCBI
|
|
3
|
Taylor J, Xiao W and Abdel-Wahab O: Diagnosis and classification of hematologic malignancies on the basis of genetics. Blood. 130:410–423. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
The Lancet Haematology, . The global burden of haematological diseases. Lancet Haematol. 5:e12018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Krok-Schoen JL, Fisher JL, Stephens JA, Mims A, Ayyappan S, Woyach JA and Rosko AE: Incidence and survival of hematological cancers among adults ages ≥75 years. Cancer Med. 7:3425–3433. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Egesie OJ, Agaba PA, Silas OA, Achenbach C, Zoakah A, Agbaji OO, Madaki JA, Okeke EN, Hou L, Sagay AS and Murphy R: Presentation and survival in patients with hematologic malignancies in Jos, Nigeria: A retrospective cohort analysis. J Med Trop. 20:49–56. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Khayr W, Haddad RY and Noor SA: Infections in hematological malignancies. Dis Mon. 58:239–249. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Harapan H, Itoh N, Yufika A, Winardi W, Keam S, Te H, Megawati D, Hayati Z, Wagner AL and Mudatsir M: Coronavirus disease 2019 (COVID-19): A literature review. J Infect Public Health. 13:667–673. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Esakandari H, Nabi-Afjadi M, Fakkari-Afjadi J, Farahmandian N, Miresmaeili SM and Bahreini E: A comprehensive review of COVID-19 characteristics. Biol Proced Online. 22:192020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Muralidar S, Ambi SV, Sekaran S and Krishnan UM: The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2. Biochimie. 179:85–100. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Neagu M, Calina D, Docea AO, Constantin C, Filippini T, Vinceti M, Drakoulis N, Poulas K, Nikolouzakis TK, Spandidos DA and Tsatsakis A: Back to basics in COVID-19: Antigens and antibodies-completing the puzzle. J Cell Mol Med. 25:4523–4533. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sarkar C, Mondal M, Torequl Islam M, Martorell M, Docea AO, Maroyi A, Sharifi-Rad J and Calina D: Potential therapeutic options for COVID-19: Current status, challenges, and future perspectives. Front Pharmacol. 11:5728702020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kostoff RN, Kanduc D, Porter AL, Shoenfeld Y, Calina D, Briggs MB, Spandidos DA and Tsatsakis A: Vaccine- and natural infection-induced mechanisms that could modulate vaccine safety. Toxicol Rep. 7:1448–1458. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rudrapal M, Khairnar SJ, Borse LB and Jadhav AG: Coronavirus disease-2019 (COVID-19): An updated review. Drug Res (Stuttg). 70:389–400. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Calina D, Hernández AF, Hartung T, Egorov AM, Izotov BN, Nikolouzakis TK, Tsatsakis A, Vlachoyiannopoulos PG and Docea AO: Challenges and scientific prospects of the newest generation of mRNA-based vaccines against SARS-CoV-2. Life (Basel). 11:9072021.PubMed/NCBI
|
|
16
|
Islam MT, Salehi B, Karampelas O, Sharifi-Rad J, Docea AO, Martorell M and Calina D: High skin melanin content, vitamin D deficiency and immunity: Potential interference for severity of COVID-19. Farmacia. 68:970–983. 2020. View Article : Google Scholar
|
|
17
|
Lotfi M, Hamblin MR and Rezaei N: COVID-19: Transmission, prevention, and potential therapeutic opportunities. Clin Chim Acta. 508:254–266. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Giammaria D and Pajewski A: Can early treatment of patients with risk factors contribute to managing the COVID-19 pandemic? J Glob Health. 10:0103772020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
WHO, . Weekly epidemiological update-2 February 2021. Journal;2021.
|
|
20
|
Lee ACK and Morling JR: COVID-19 vaccine dilemmas. Public Health. 2021. View Article : Google Scholar
|
|
21
|
Badiani AA, Patel JA, Ziolkowski K and Nielsen FBH: Pfizer: The miracle vaccine for COVID-19? Public Health Pract (Oxf). 1:1000612020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Calina D, Docea AO, Petrakis D, Egorov AM, Ishmukhametov AA, Gabibov AG, Shtilman MI, Kostoff R, Carvalho F, Vinceti M, et al: Towards effective COVID-19 vaccines: Updates, perspectives and challenges (review). Int J Mol Med. 46:3–16. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Calina D, Sarkar C, Arsene AL, Salehi B, Docea AO, Mondal M, Islam MT, Zali A and Sharifi-Rad J: Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development. Immunol Res. 68:315–324. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Alfano V and Ercolano S: The efficacy of lockdown against COVID-19: A cross-country panel analysis. Appl Health Econ Health Policy. 18:509–517. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Papakonstantinou E, Pierouli K, Mitsis T, Diakou KI, Palaiogeorgou AM, Bacopoulou F, Chrousos GP, Eliopoulos E and Vlachakis D: COVID-19 global social lockdowns: Energy-related, psychological, epigenetic, health and environmental impacts (review). Int J Epigen. 1:82021. View Article : Google Scholar
|
|
26
|
Calina D, Hartung T, Mardare I, Mitroi M, Poulas K, Tsatsakis A, Rogoveanu I and Docea AO: COVID-19 pandemic and alcohol consumption: Impacts and interconnections. Toxicol Rep. 8:529–535. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Moraliyage H, De Silva D, Ranasinghe W, Adikari A, Alahakoon D, Prasad R, Lawrentschuk N and Bolton D: Cancer in lockdown: Impact of the COVID-19 pandemic on patients with cancer. Oncologist. 26:e342–e344. 2020.PubMed/NCBI
|
|
28
|
Rubinstein SM and Warner JL: COVID-19 and haematological malignancy: Navigating a narrow strait. Lancet Haematol. 7:e701–e703. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang Y, Duan Z, Ma Z, Mao Y, Li X, Wilson A, Qin H, Ou J, Peng K, Zhou F, et al: Epidemiology of mental health problems among patients with cancer during COVID-19 pandemic. Transl Psychiatry. 10:2632020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Islam MT, Hossen M, Kamaz Z, Zali A, Kumar M, Docea AO, Arsene AL, Călina D and Sharifi-Rad J: The role of hmgb1 in the immune response to sars-cov-2 infection: From pathogenesis towards a new potential therapeutic target. Farmacia. 69:621–634. 2021.
|
|
31
|
Isidori A, de Leval L, Gergis U, Musto P and Porcu P: Management of patients with hematologic malignancies during the COVID-19 pandemic: Practical considerations and lessons to be learned. Front Oncol. 10:14392020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Binder AF, Handley NR, Wilde L, Palmisiano N and Lopez AM: Treating hematologic malignancies during a pandemic: Utilizing telehealth and digital technology to optimize care. Front Oncol. 10:11832020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jørgensen JT: Twenty years with personalized medicine: Past, present, and future of individualized pharmacotherapy. Oncologist. 24:e432–e440. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Divaris K: Fundamentals of precision medicine. Compend Contin Educ Dent. 38 (8 Suppl):S30–S32. 2017.PubMed/NCBI
|
|
35
|
Manzoni C, Kia DA, Vandrovcova J, Hardy J, Wood NW, Lewis PA and Ferrari R: Genome, transcriptome and proteome: The rise of omics data and their integration in biomedical sciences. Brief Bioinform. 19:286–302. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
D'Souza RN, Dunnwald M, Frazier-Bowers S, Polverini PJ, Wright JT, de Rouen T and Vieira AR; Translational Genetics Meeting Group, : Translational genetics: Advancing fronts for craniofacial health. J Dent Res. 92:1058–1064. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Vlachakis D and Kossida S: Antibody drug conjugate bioinformatics: Drug delivery through the letterbox. Comput Math Methods Med. 2013:2823982013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Geres H and Kotchetkov R: Nursing in patients with hematological malignancies. Int J Hematol Oncol. 9:IJH242020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Vedsted P and Olesen F: Early diagnosis of cancer-the role of general practice. Scand J Prim Health Care. 27:193–194. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li J, Smith A, Crouch S, Oliver S and Roman E: Estimating the prevalence of hematological malignancies and precursor conditions using data from haematological malignancy research network (HMRN). Cancer Causes Control. 27:1019–1026. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang Y, Zhang B, Zhang X, Wang X, Cheng J and Chen B: Detection and identification of hematologic malignancies and solid tumors by an electrochemical technique. PLoS One. 11:e01538212016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Dapkevičiūtė A, Šapoka V, Martynova E and Pečeliūnas V: Time from symptom onset to diagnosis and treatment among haematological malignancies: Influencing factors and associated negative outcomes. Medicina (Kaunas). 55:2382019. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Howell DA, Smith AG, Jack A, Patmore R, Macleod U, Mironska E and Roman E: Time-to-diagnosis and symptoms of myeloma, lymphomas and leukaemias: A report from the haematological malignancy research network. BMC Hematol. 13:92013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Prakash G, Kaur A, Malhotra P, Khadwal A, Sharma P, Suri V, Varma N and Varma S: Current role of genetics in hematologic malignancies. Indian J Hematol Blood Transfus. 32:18–31. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Mariotto AB, Noone AM, Howlader N, Cho H, Keel GE, Garshell J, Woloshin S and Schwartz LM: Cancer survival: An overview of measures, uses, and interpretation. J Natl Cancer Inst Monogr. 2014:145–186. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gray TF, Temel JS and El-Jawahri A: Illness and prognostic understanding in patients with hematologic malignancies. Blood Rev. 45:1006922021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Button E, Chan RJ, Chambers S, Butler J and Yates P: A systematic review of prognostic factors at the end of life for people with a hematological malignancy. BMC Cancer. 17:2132017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
de Vries VA, Müller MCA, Arbous MS, Biemond BJ, Blijlevens NMA, Kusadasi N, Span LRF, Vlaar APJ, van Westerloo DJ, Kluin-Nelemans HC, et al: Long-term outcome of patients with a hematologic malignancy and multiple organ failure admitted at the intensive care. Crit Care Med. 47:e120–e128. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kansara RR and Speziali C: Immunotherapy in hematologic malignancies. Curr Oncol. 27 (Suppl 2):S124–S131. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Nelson MH and Paulos CM: Novel immunotherapies for hematologic malignancies. Immunol Rev. 263:90–105. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Méndez-Ferrer S, Bonnet D, Steensma DP, Hasserjian RP, Ghobrial IM, Gribben JG, Andreeff M and Krause DS: Bone marrow niches in haematological malignancies. Nat Rev Cancer. 20:285–298. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Boland MJ, Nazor KL and Loring JF: Epigenetic regulation of pluripotency and differentiation. Circ Res. 115:311–324. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, Shin JJ, Harbom KM, Beaty R, Pappou E, et al: Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell. 21:430–446. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Im AP, Sehgal AR, Carroll MP, Smith BD, Tefferi A, Johnson DE and Boyiadzis M: DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: Associations with prognosis and potential treatment strategies. Leukemia. 28:1774–1783. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Li KK, Luo LF, Shen Y, Xu J, Chen Z and Chen SJ: DNA methyltransferases in hematologic malignancies. Semin Hematol. 50:48–60. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Wakita S, Yamaguchi H, Omori I, Terada K, Ueda T, Manabe E, Kurosawa S, Iida S, Ibaraki T, Sato Y, et al: Mutations of the epigenetics-modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia. Leukemia. 27:1044–1052. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Cairns RA, Iqbal J, Lemonnier F, Kucuk C, de Leval L, Jais JP, Parrens M, Martin A, Xerri L, Brousset P, et al: IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood. 119:1901–1903. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Lemonnier F, Couronné L, Parrens M, Jaïs JP, Travert M, Lamant L, Tournillac O, Rousset T, Fabiani B, Cairns RA, et al: Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. Blood. 120:1466–1469. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Azad N, Zahnow CA, Rudin CM and Baylin SB: The future of epigenetic therapy in solid tumours-lessons from the past. Nat Rev Clin Oncol. 10:256–266. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Cheng Y, He C, Wang M, Ma X, Mo F, Yang S, Han J and Wei X: Targeting epigenetic regulators for cancer therapy: Mechanisms and advances in clinical trials. Signal Transduct Target Ther. 4:622019. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, Zhang Z, You H, Wu M, Zheng Q, et al: Patients with cancer appear more vulnerable to SARS-CoV-2: A multicenter study during the COVID-19 outbreak. Cancer Discov. 10:783–791. 2020.PubMed/NCBI
|
|
62
|
Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, Martín-Moro F, Razanamahery J, Riches JC, Zwicker J, et al: Outcomes of patients with hematologic malignancies and COVID-19: A systematic review and meta-analysis of 3377 patients. Blood. 136:2881–2892. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Malard F, Genthon A, Brissot E, van de Wyngaert Z, Marjanovic Z, Ikhlef S, Banet A, Lapusan S, Sestilli S, Corre E, et al: COVID-19 outcomes in patients with hematologic disease. Bone Marrow Transplant. 55:2180–2184. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Wang B, Van Oekelen O, Mouhieddine TH, Del Valle DM, Richter J, Cho HJ, Richard S, Chari A, Gnjatic S, Merad M, et al: A tertiary center experience of multiple myeloma patients with COVID-19: Lessons learned and the path forward. J Hematol Oncol. 13:942020. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Wang LQ, Tan Su Yin E, Wei GQ, Hu YX, Nagler A and Huang H: Weathering the storm: COVID-19 infection in patients with hematological malignancies. J Zhejiang Univ Sci B. 21:921–939. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ and Prescott HC: Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review. JAMA. 324:782–793. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Vlachakis D, Papakonstantinou E, Mitsis T, Pierouli K, Diakou I, Chrousos G and Bacopoulou F: Molecular mechanisms of the novel coronavirus SARS-CoV-2 and potential anti-COVID19 pharmacological targets since the outbreak of the pandemic. Food Chem Toxicol. 146:1118052020. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Psaltopoulou T, Sergentanis TN, Pappa V, Politou M, Terpos E, Tsiodras S, Pavlakis GN and Dimopoulos MA: The emerging role of convalescent plasma in the treatment of COVID-19. Hemasphere. 4:e4092020. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Liu STH, Lin HM, Baine I, Wajnberg A, Gumprecht JP, Rahman F, Rodriguez D, Tandon P, Bassily-Marcus A, Bander J, et al: Convalescent plasma treatment of severe COVID-19: A propensity score-matched control study. Nat Med. 26:1708–1713. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Jamilloux Y, Henry T, Belot A, Viel S, Fauter M, El Jammal T, Walzer T, François B and Sève P: Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev. 19:1025672020. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, Psaltopoulou T, Gerotziafas G and Dimopoulos MA: Hematological findings and complications of COVID-19. Am J Hematol. 95:834–847. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Calina D, Hartung T, Docea AO, Spandidos DA, Egorov AM, Shtilman MI, Carvalho F and Tsatsakis A: COVID-19 vaccines: Ethical framework concerning human challenge studies. Daru. 28:807–812. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Hernández AF, Calina D, Poulas K, Docea AO and Tsatsakis AM: Safety of COVID-19 vaccines administered in the EU: Should we be concerned? Toxicol Rep. 8:871–879. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Desai A, Gainor JF, Hegde A, Schram AM, Curigliano G, Pal S, Liu SV, Halmos B, Groisberg R, Grande E, et al: COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. Nat Rev Clin Oncol. 18:313–319. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Gosain R, Abdou Y, Singh A, Rana N, Puzanov I and Ernstoff MS: COVID-19 and cancer: A comprehensive review. Curr Oncol Rep. 22:532020. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
García-Suárez J, de la Cruz J, Cedillo Á, Llamas P, Duarte R, Jiménez-Yuste V, Hernández-Rivas J, Gil-Manso R, Kwon M, Sánchez-Godoy P, et al: Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: Lessons from a large population-based registry study. J Hematol Oncol. 13:1332020. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Wood WA, Neuberg DS, Thompson JC, Tallman MS, Sekeres MA, Sehn LH, Anderson KC, Goldberg AD, Pennell NA, Niemeyer CM, et al: Outcomes of patients with hematologic malignancies and COVID-19: A report from the ASH research collaborative data Hub. Blood Adv. 4:5966–5975. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
ElGohary GM, Hashmi S, Styczynski J, Kharfan-Dabaja MA, Alblooshi RM, de la Cámara R, Mohmed S, Alshaibani A, Cesaro S, Abd El-Aziz N, et al: The risk and prognosis of COVID-19 infection in cancer patients: A systematic review and meta-analysis. Hematol Oncol Stem Cell Ther. Jul 30–2020.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
79
|
He W, Chen L, Chen L, Yuan G, Fang Y, Chen W, Wu D, Liang B, Lu X, Ma Y, et al: COVID-19 in persons with haematological cancers. Leukemia. 34:1637–1645. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Kuderer NM, Hill JA, Carpenter PA and Lyman GH: Challenges and opportunities for COVID-19 vaccines in patients with cancer. Cancer Invest. 39:205–213. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Luker GD and Boettcher AN: Impact of COVID-19 on clinical care and research in cancer imaging: Where we are now. Radiol Imaging Cancer. 3:e2100032021. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Vlachakis D, Fakourelis P, Megalooikonomou V, Makris C and Kossida S: DrugOn: A fully integrated pharmacophore modeling and structure optimization toolkit. PeerJ. 3:e7252015. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Fong D, San Nicolò KO, Alber M and Mitterer M: Evaluating the longitudinal effectiveness of preventive measures against COVID-19 and seroprevalence of IgG antibodies to SARS-CoV-2 in cancer outpatients and healthcare workers. Wien Klin Wochenschr. 133:359–363. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Cavalcanti IDL and Soares JCS: Impact of COVID-19 on cancer patients: A review. Asia Pac J Clin Oncol. 17:186–192. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, Jia P, Guan HQ, Peng L, Chen Y, et al: Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 31:894–901. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Levy I, Sharf G, Norman S and Tadmor T: The impact of COVID-19 on patients with hematological malignancies: The mixed-method analysis of an Israeli national survey. Support Care Cancer. 1–9. 2021.(Epub ahead of print).
|
